Trisk Bio
Trisk Bio, based in Stevenage, UK, is a biotech firm focused on revolutionizing the manufacturing of biological therapies, including gene therapies, through automation and robotics.
Funding and Investors
Trisk Bio has successfully raised an $11M seed round. The funding round was led by top-tier investors from both the United States and the United Kingdom, demonstrating strong international confidence in the company's vision and technological achievements. This investment supports Trisk Bio's ambitious plans to revolutionize the manufacturing process for biological therapies through automation and innovation.
Location and Accessibility
Trisk Bio is situated in Stevenage, UK. This location offers convenient access to central hubs, being a short train commute from Central London, East London, and Cambridge. The strategic positioning allows the company to tap into a rich pool of talent and resources, facilitating smooth collaborations with nearby academic and biotechnological institutions.
Cutting-Edge Manufacturing Facility
Trisk Bio is in the process of building a fully automated facility dedicated to manufacturing biological therapies, with a particular focus on gene therapies. The company aims to eliminate the traditional scale-up process in manufacturing by implementing parallelized production using robotic systems. This approach will enable rapid transition from development to market, enhancing efficiency and innovation in the biotech sector.
Global Talent and Team Structure
Trisk Bio is committed to hiring talent globally and sponsors visas to attract the best professionals. The company has expertise across diverse fields, including biology, regulatory affairs, mechanical engineering, and physics. Despite the aspiration to remain a small team during the initial phase of their manufacturing facility's construction, the firm leverages a high level of interdisciplinary expertise to drive its pioneering projects.
COVID-19 Testing Initiatives
Trisk Bio has a proven track record in the biotechnology industry, having previously collaborated on the deployment of mass COVID-19 tests across the UK. This experience highlights the company's capability to manage large-scale health initiatives and respond to urgent public health needs with efficient solutions.
